FTC REPORT RECOMMENDS CHANGES TO HATCH-WAXMAN ACT Generic Drug Entry Prior to Patent Expiration | Secondary Sources | Westlaw

FTC REPORT RECOMMENDS CHANGES TO HATCH-WAXMAN ACT Generic Drug Entry Prior to Patent Expiration | Secondary Sources | Westlaw

View on Westlaw or start a FREE TRIAL today, FTC REPORT RECOMMENDS CHANGES TO HATCH-WAXMAN ACT Generic Drug Entry Prior to Patent Expiration, Secondary Sources
Skip Page Header

FTC REPORT RECOMMENDS CHANGES TO HATCH-WAXMAN ACT Generic Drug Entry Prior to Patent Expiration

10 No. 3 ANHLLR 1Andrews Health Law Litigation Reporter (Approx. 3 pages)

FTC REPORT RECOMMENDS CHANGES TO HATCH-WAXMAN ACT Generic Drug Entry Prior to Patent Expiration

10 No. 3 ANHLLR 1Andrews Health Law Litigation Reporter (Approx. 3 pages)

10 No. 3 Andrews Health L. Litig. Rep. 1
Andrews Health Law Litigation Reporter
September 13, 2002
FTC Activity:
Copyright (c) 2002 Andrews Publications

FTC REPORT RECOMMENDS CHANGES TO HATCH-WAXMAN ACT

Generic Drug Entry Prior to Patent Expiration

Generic drugs make up an ever-increasing share of the prescription drug market, but some changes to the Hatch-Waxman Act would further streamline the approval process for generics and make it more difficult for brand-name and generic manufacturers to...
End of Document© 2023 Thomson Reuters. No claim to original U.S. Government Works.